Novartis patents expiration
1. Afinitor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778962 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(1 year, 7 months ago) | |
| US8436010 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(1 year, 7 months ago) | |
|
US8778962 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 1 month ago) | |
|
US8436010 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 1 month ago) | |
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(2 years from now) | |
|
US8410131 (Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(2 years from now) | |
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
Market Authorisation Date: 30 March, 2009
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of ...
Dosage: TABLET;ORAL
AFINITOR family patents
2. Amturnide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8183295 | NOVARTIS | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
May, 2023
(4 months ago) | |
Market Authorisation Date: 21 December, 2010
Treatment: NA
Dosage: TABLET;ORAL
AMTURNIDE family patents
3. Arcapta Neohaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
Drugs and Companies using INDACATEROL MALEATE ingredient
Market Authorisation Date: 01 July, 2011
Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema
Dosage: POWDER;INHALATION
ARCAPTA NEOHALER family patents
4. Ciprodex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9402805 | NOVARTIS | Method of treating middle ear infections |
Sep, 2022
(1 year, 15 days ago) | |
| US9149486 | NOVARTIS | Method of treating middle ear infections |
Sep, 2022
(1 year, 15 days ago) | |
| US9345714 | NOVARTIS | Method of treating middle ear infections |
Sep, 2022
(1 year, 15 days ago) | |
| US8846650 | NOVARTIS | Method of treating middle ear infections |
Jun, 2025
(1 year, 8 months from now) | |
Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient
Market Authorisation Date: 18 July, 2003
Treatment: Treatment of acute otitis media; Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS;OTIC
CIPRODEX family patents
5. Exforge Hct patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101599 | NOVARTIS | Pharmaceutical composition containing anti-hypertensive agents |
May, 2023
(4 months ago) | |
| US8475839 | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
May, 2023
(4 months ago) | |
|
US8475839 (Pediatric) | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
Nov, 2023
(a month from now) | |
Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient
Market Authorisation Date: 30 April, 2009
Treatment: NA
Dosage: TABLET;ORAL
EXFORGE HCT family patents
6. Gilenya patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(2 years from now) | |
|
US8324283 (Pediatric) | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Sep, 2026
(3 years from now) | |
| US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(3 years from now) | |
|
US9187405 (Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(4 years from now) | |
| US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(4 years from now) | |
| US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(8 years from now) | |
|
US9592208 (Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(9 years from now) | |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
Market Authorisation Date: 21 September, 2010
Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; T...
Dosage: CAPSULE;ORAL
GILENYA family patents
7. Gleevec patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6958335 (Pediatric) | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Jun, 2022
(1 year, 3 months ago) | |
Drugs and Companies using IMATINIB MESYLATE ingredient
Market Authorisation Date: 18 April, 2003
Treatment: NA
Dosage: TABLET;ORAL
GLEEVEC family patents
8. Hycamtin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8158645 | NOVARTIS | Compound, corresponding compositions, preparation and/or treatment methods |
Dec, 2024
(1 year, 2 months from now) | |
Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 11 October, 2007
Treatment: NA
Dosage: CAPSULE;ORAL
HYCAMTIN family patents
9. Ilevro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947295 | NOVARTIS | Ophthalmic compositions containing a synergistic combination of two polymers |
Jun, 2024
(8 months from now) | |
| US9662398 | NOVARTIS | Carboxylvinyl polymer-containing nanoparticle suspensions |
Dec, 2030
(7 years from now) | |
| US8921337 | NOVARTIS | Carboxyvinyl polymer-containing nanoparticle suspensions |
Mar, 2032
(8 years from now) | |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
ILEVRO family patents
10. Izba patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9144561 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Mar, 2029
(5 years from now) | |
| US8754123 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
May, 2029
(5 years from now) | |
| US8178582 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) | |
| US8722735 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) | |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 15 May, 2014
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
IZBA family patents
11. Kisqali patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(4 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(6 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(7 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(5 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(6 years from now) | |
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 10, 2024 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
Market Authorisation Date: 13 March, 2017
Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-ba...
Dosage: TABLET;ORAL
KISQALI family patents
12. Kisqali Femara Co-pack (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(4 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(6 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(7 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(5 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(6 years from now) | |
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(8 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 10, 2024 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
Market Authorisation Date: 04 May, 2017
Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; As initial endocrine-based the...
Dosage: TABLET;ORAL
KISQALI FEMARA CO-PACK (COPACKAGED) family patents
13. Leqvio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9074213 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Mar, 2022
(1 year, 6 months ago) | |
| US8546143 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Apr, 2022
(1 year, 5 months ago) | |
| US8232383 | NOVARTIS | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb, 2023
(7 months ago) | |
| US11078485 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(a month from now) | |
| US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(3 months from now) | |
| US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(5 months from now) | |
| US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(5 months from now) | |
| US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(5 months from now) | |
| US11530408 | NOVARTIS | Therapeutic compositions |
May, 2024
(7 months from now) | |
| US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(3 years from now) | |
| US10131907 | NOVARTIS | Glycoconjugates of RNA interference agents |
Aug, 2028
(4 years from now) | |
| US8828956 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| US10806791 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| US9370582 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| US8106022 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(6 years from now) | |
| US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10590418 | NOVARTIS | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
Jul, 2022
(1 year, 2 months ago) | |
| US10266825 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(a month from now) | |
| US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(4 years from now) | |
| US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 2025-12-22
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...
Dosage: SOLUTION;SUBCUTANEOUS
LEQVIO family patents
14. Mayzent patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7939519 | NOVARTIS | Immunosuppresant compounds and compositions |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492441 | NOVARTIS | Dosage regimen of an S1P receptor agonist |
Nov, 2030
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 26, 2024 |
| M (M) | Mar 1, 2025 |
Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient
NCE-1 date: 2023-03-27
Market Authorisation Date: 26 March, 2019
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose
Dosage: TABLET;ORAL
MAYZENT family patents
15. Mekinist patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(3 years from now) | |
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(1 year, 8 months from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(2 years from now) | |
|
US7378423 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Nov, 2027
(4 years from now) | |
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(7 years from now) | |
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(7 years from now) | |
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(7 years from now) | |
| US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
| US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
| US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
| US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
|
US9271941 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9155706 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US8580304 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9399021 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 16, 2030 |
| New Product (NP) | Mar 16, 2026 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Market Authorisation Date: 16 March, 2023
Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an...
Dosage: SOLUTION;ORAL
MEKINIST family patents
16. Moxeza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9114168 | NOVARTIS | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(5 years from now) | |
| US8450311 | NOVARTIS | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(5 years from now) | |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 19 November, 2010
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
MOXEZA family patents
17. Nevanac patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324281 | NOVARTIS | Topical nepafenac formulations |
Dec, 2025
(2 years from now) | |
| US8071648 | NOVARTIS | Topical nepafenac formulations |
Dec, 2025
(2 years from now) | |
| US7834059 | NOVARTIS | Topical nepafenac formulations |
Jan, 2027
(3 years from now) | |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 19 August, 2005
Treatment: Method of treating ocular inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
NEVANAC family patents
18. Patanase patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399508 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Sep, 2022
(1 year, 11 days ago) | |
| US7977376 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Feb, 2023
(7 months ago) | |
|
US8399508 (Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Mar, 2023
(6 months ago) | |
|
US7977376 (Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Aug, 2023
(a month ago) | |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2008
Treatment: Allergic rhinitis
Dosage: SPRAY, METERED;NASAL
PATANASE family patents
19. Piqray patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(5 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 24, 2024 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 2023-05-25
Market Authorisation Date: 24 May, 2019
Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer
Dosage: TABLET;ORAL
PIQRAY family patents
20. Promacta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(10 months ago) | |
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(1 year, 9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(4 months ago) | |
| US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(4 months ago) | |
|
US7795293 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(a month from now) | |
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(2 years from now) | |
| US8052993 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8071129 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8052994 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8828430 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8062665 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
|
US8062665 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(4 years from now) | |
|
US8828430 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(4 years from now) | |
|
US8052993 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(4 years from now) | |
|
US8052994 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(4 years from now) | |
|
US8071129 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 20 November, 2008
Treatment: Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic imm...
Dosage: TABLET;ORAL
PROMACTA family patents
21. Promacta Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(10 months ago) | |
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(1 year, 9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(4 months ago) | |
| US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(4 months ago) | |
|
US7795293 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(a month from now) | |
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 24 August, 2015
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis...
Dosage: FOR SUSPENSION;ORAL
PROMACTA KIT family patents
22. Reclast patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8052987 | NOVARTIS | Method of administering bisphosphonates |
Oct, 2023
(28 days from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(4 years from now) | |
|
US7932241 (Pediatric) | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(4 years from now) | |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 16 April, 2007
Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis
Dosage: INJECTABLE;INTRAVENOUS
RECLAST family patents
23. Rydapt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222244 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2022
(10 months ago) | |
| US7973031 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2028
(5 years from now) | |
| US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 28, 2024 |
Drugs and Companies using MIDOSTAURIN ingredient
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolid...
Dosage: CAPSULE;ORAL
RYDAPT family patents
24. Scemblix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
May, 2033
(9 years from now) | |
| US11407735 | NOVARTIS | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 29, 2026 |
| Orphan Drug Exclusivity (ODE) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: 2025-10-29
Market Authorisation Date: 29 October, 2021
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
Dosage: TABLET;ORAL
SCEMBLIX family patents
25. Seebri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(5 years from now) | |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: NA
Dosage: POWDER;INHALATION
SEEBRI family patents
26. Tafinlar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8415345 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(6 years from now) | |
| US7994185 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(6 years from now) | |
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(1 year, 8 months from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(2 years from now) | |
| US9233956 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
May, 2029
(5 years from now) | |
|
US9233956 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Nov, 2029
(6 years from now) | |
|
US8415345 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(6 years from now) | |
|
US7994185 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(6 years from now) | |
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(7 years from now) | |
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(7 years from now) | |
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(7 years from now) | |
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(10 years from now) | |
| US11504333 | NOVARTIS | Pharmaceutical composition |
Jun, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 16, 2030 |
| New Indication (I) | Jun 22, 2025 |
| Pediatric Exclusivity (PED) | Dec 22, 2025 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: Tafinlar is indicated, in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic thera...
Dosage: CAPSULE;ORAL
TAFINLAR family patents
27. Tasigna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(2 months ago) | |
| US8415363 | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(2 years from now) | |
| US8163904 | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Aug, 2028
(4 years from now) | |
| US9061029 | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Apr, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7169791 (Pediatric) | NOVARTIS | Inhibitors of tyrosine kinases |
Jan, 2024
(3 months from now) | |
| US8501760 | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jul, 2026
(2 years from now) | |
| US8389537 | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(2 years from now) | |
|
US8415363 (Pediatric) | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(3 years from now) | |
|
US8389537 (Pediatric) | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(3 years from now) | |
|
US8501760 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jan, 2027
(3 years from now) | |
| US8293756 | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Sep, 2027
(3 years from now) | |
|
US8293756 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Mar, 2028
(4 years from now) | |
|
US8163904 (Pediatric) | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Feb, 2029
(5 years from now) | |
|
US9061029 (Pediatric) | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Oct, 2032
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 23, 2028 |
| Pediatric Exclusivity (PED) | Mar 23, 2029 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 29 October, 2007
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); A method for the treatment of leukemias; Treatment of newly diagnosed philadelphia chromosome positive chronic myeloid ...
Dosage: CAPSULE;ORAL
TASIGNA family patents
28. Tekamlo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8613949 | NOVARTIS | Galenical formulations of organic compounds |
Dec, 2029
(6 years from now) | |
Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 26 August, 2010
Treatment: NA
Dosage: TABLET;ORAL
TEKAMLO family patents
29. Travatan Z patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8388941 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Sep, 2027
(3 years from now) | |
| US8323630 | NOVARTIS | Self-preserved aqueous pharmaceutical compositions |
Sep, 2027
(3 years from now) | |
| US8268299 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Oct, 2029
(6 years from now) | |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 21 September, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
TRAVATAN Z family patents
30. Triesence patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8211880 | NOVARTIS | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Mar, 2029
(5 years from now) | |
| US8128960 | NOVARTIS | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Dec, 2029
(6 years from now) | |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 29 November, 2007
Treatment: Visualization during vitrectomy procedures; Treatment of ophthalmic disorders
Dosage: INJECTABLE;INTRAVITREAL
TRIESENCE family patents
31. Tykerb patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8821927 | NOVARTIS | Pharmaceutical composition |
Sep, 2029
(5 years from now) | |
Drugs and Companies using LAPATINIB DITOSYLATE ingredient
Market Authorisation Date: 13 March, 2007
Treatment: NA
Dosage: TABLET;ORAL
TYKERB family patents
32. Tyzeka patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(17 days ago) | |
| US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(17 days ago) | |
Drugs and Companies using TELBIVUDINE ingredient
Market Authorisation Date: 25 October, 2006
Treatment: Treatment of chronic hepatitis b in adult patients
Dosage: TABLET;ORAL
TYZEKA family patents
33. Utibron patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(5 years from now) | |
Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
UTIBRON family patents
34. Valturna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168616 | NOVARTIS | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
Jul, 2026
(2 years from now) | |
Drugs and Companies using ALISKIREN HEMIFUMARATE; VALSARTAN ingredient
Market Authorisation Date: 16 September, 2009
Treatment: NA
Dosage: TABLET;ORAL
VALTURNA family patents
35. Vijoice patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(5 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 24, 2024 |
| Orphan Drug Exclusivity (ODE) | Apr 5, 2029 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 2023-05-25
Market Authorisation Date: 05 April, 2022
Treatment: NA
Dosage: TABLET;ORAL
VIJOICE family patents
36. Votrient patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7105530 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Oct, 2023
(20 days from now) | |
Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2009
Treatment: NA
Dosage: TABLET;ORAL
VOTRIENT family patents
37. Xiidra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7928122 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 1 month from now) | |
| US7745460 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 1 month from now) | |
| US7314938 | NOVARTIS | Modulators of cellular adhesion |
Mar, 2025
(1 year, 5 months from now) | |
| US8084047 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(2 years from now) | |
| US9890141 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216174 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 1 month from now) | |
| US10124000 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 1 month from now) | |
| US7790743 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 1 month from now) | |
| US8592450 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(2 years from now) | |
| US8367701 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(5 years from now) | |
| US9447077 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(5 years from now) | |
| US8168655 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2029
(5 years from now) | |
| US9353088 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(7 years from now) | |
| US8927574 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Nov, 2030
(7 years from now) | |
| US9085553 | NOVARTIS | LFA-1 inhibitor and methods of preparation and polymorph thereof |
Jul, 2033
(9 years from now) | |
| US11058677 | NOVARTIS | LFA-1 inhibitor formulations |
Dec, 2033
(10 years from now) | |
Drugs and Companies using LIFITEGRAST ingredient
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC
XIIDRA family patents
38. Zometa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(1 year, 7 months from now) | |
|
US8324189 (Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(2 years from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(4 years from now) | |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 20 August, 2001
Treatment: Multiple myeloma; Bone metastases; Hypercalcemia of malignancy
Dosage: INJECTABLE;INTRAVENOUS
ZOMETA family patents
39. Zykadia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9018204 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(7 months ago) | |
| US8188276 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(7 months ago) | |
| US8835430 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(7 months ago) | |
| US9416112 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(7 months ago) | |
| US7893074 | NOVARTIS | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2026
(2 years from now) | |
| US8399450 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(4 years from now) | |
| US7964592 | NOVARTIS | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2028
(4 years from now) | |
| US8039479 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Jun, 2030
(6 years from now) | |
| US9309229 | NOVARTIS | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
Jan, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377921 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(4 years from now) | |
| US8703787 | NOVARTIS | Methods of using ALK inhibitors |
Feb, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | May 26, 2024 |
Drugs and Companies using CERITINIB ingredient
Market Authorisation Date: 18 March, 2019
Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)
Dosage: TABLET;ORAL
ZYKADIA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic